Literature DB >> 9118528

Very early noninvasive detection of acute experimental nonreperfused myocardial infarction with 99mTc-labeled glucarate.

J Narula1, A Petrov, K Y Pak, B C Lister, B A Khaw.   

Abstract

BACKGROUND: 99mTc glucarate has recently been reported to be an infarct-avid agent. The feasibility of imaging with 99mTc glucarate was evaluated for the early diagnosis of nonreperfused and reperfused myocardial infarction and compared with localization of simultaneously administered 111In anti-myosin. METHODS AND
RESULTS: Four groups of six rabbits each were studied. The left anterior descending coronary artery (LAD) was kept persistently occluded (n = 6) or reperfused after 40 minutes (n = 6) in rabbits. After confirmation of LAD occlusion by 201Tl scintigraphy, a mixture of 99mTc glucarate (15.7 +/- 1.6 mCi) and 111In anti-myosin (0.53 +/- 0.03 mCi) was administered intravenously. Another group of rabbits (n = 6) with 5 or 15 minutes of LAD occlusion were used to assess the affinity of 99mTc glucarate for the ischemic myocardium. The remaining 6 rabbits with reperfused myocardial infarction were used for the assessment of subcellular localization of 99mTc glucarate. 99mTc glucarate cleared rapidly from circulation (elimination t1/2, 36 minutes). Infarcts were visualized within 10 minutes in reperfused and within 30 minutes in nonreperfused coronary territories after intravenous administration. 111In anti-myosin delineated reperfused infarcts within 1 to 3 hours, but no uptake was seen in persistently occluded rabbits. 99mTc glucarate uptake in reperfused and nonreperfused infarct centers was 28 and 12 times greater, respectively, than that in normal myocardium (P = .0001). A direct correlation between glucarate and anti-myosin localization (r = .60 for nonreperfused; 0.76 for reperfused; P < .0001) was observed. Ischemic hearts showed no glucarate uptake. Subcellularly, 99mTc glucarate localized predominantly in the nuclear fraction of the infarct, with lesser extents in the mitochondrial and cytoplasmic fractions.
CONCLUSIONS: Noninvasive imaging of myocardial infarcts with 99mTc glucarate is possible within minutes in persistently occluded or reperfused myocardial infarcts. Early detectability results from the rapid blood clearance and high avidity of glucarate for the acutely necrotic myocardial tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118528     DOI: 10.1161/01.cir.95.6.1577

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Avidity of technetium 99m glucarate for the necrotic myocardium: in vivo and in vitro assessment.

Authors:  B A Khaw; A Nakazawa; S M O'Donnell; K Y Pak; J Narula
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

Review 2.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

3.  99mTc-glucarate kinetics differentiate normal, stunned, hibernating, and nonviable myocardium in a perfused rat heart model.

Authors:  David R Okada; Zhonglin Liu; Gerald Johnson; Delia Beju; Ban An Khaw; Robert D Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-24       Impact factor: 9.236

4.  Evaluation of Necrosis Avidity and Potential for Rapid Imaging of Necrotic Myocardium of Radioiodinated Hypocrellins.

Authors:  Qiaomei Jin; Juanzhi Zhao; Meng Gao; Yuanbo Feng; Wei Liu; Zhiqi Yin; Tiannv Li; Shaoli Song; Yicheng Ni; Jian Zhang; Dejian Huang; Dongjian Zhang
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 5.  Emergency department chest pain units and the role of radionuclide imaging.

Authors:  B G Abbott; F J Wackers
Journal:  J Nucl Cardiol       Date:  1998 Jan-Feb       Impact factor: 5.952

6.  Technetium 99m glucarate: what will be its clinical role?

Authors:  M C Gerson; A J McGoron
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

7.  Myocardial kinetics of Tc-99m glucarate in low flow, hypoxia, and aglycemia.

Authors:  D R Okada; G Johnson; Z Liu; S D Hocherman; B A Khaw; K Y Pak; R D Okada
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

8.  Cardioprotective Effects of HSP72 Administration on Ischemia-Reperfusion Injury.

Authors:  Takashi Tanimoto; Missag H Parseghian; Takehiro Nakahara; Hideki Kawai; Navneet Narula; Dongbin Kim; Robert Nishimura; Richard H Weisbart; Grace Chan; Richard A Richieri; Nezam Haider; Farhan Chaudhry; Glenn T Reynolds; John Billimek; Francis G Blankenberg; Partho P Sengupta; Artiom D Petrov; Takashi Akasaka; H William Strauss; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2017-09-19       Impact factor: 24.094

9.  Advances in radionuclide molecular imaging in myocardial biology.

Authors:  Alan R Morrison; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2010 Jan-Feb       Impact factor: 5.952

Review 10.  Small-animal SPECT and SPECT/CT: application in cardiovascular research.

Authors:  Reza Golestani; Chao Wu; René A Tio; Clark J Zeebregts; Artiom D Petrov; Freek J Beekman; Rudi A J O Dierckx; Hendrikus H Boersma; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.